The Immunoassay Handbook 2013
DOI: 10.1016/b978-0-08-097037-0.00013-0
|View full text |Cite
|
Sign up to set email alerts
|

Lab-on-a-Chip, Micro- and Nanoscale Immunoassay Systems, and Microarrays

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 252 publications
(261 reference statements)
0
7
0
Order By: Relevance
“…We monitored the progression of the assay as it travelled through the system to ensure incubation reached a steady state [ 74 ]. Reaching equilibrium, or a steady state, is desirable, as this gives the assay more stability even when having small differences in conditions between tests [ 75 , 76 ]. Figure 3 shows an example of a single experiment, using an analyte concentration of 2.5 µg/mL at a speed of 175 µL/min.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…We monitored the progression of the assay as it travelled through the system to ensure incubation reached a steady state [ 74 ]. Reaching equilibrium, or a steady state, is desirable, as this gives the assay more stability even when having small differences in conditions between tests [ 75 , 76 ]. Figure 3 shows an example of a single experiment, using an analyte concentration of 2.5 µg/mL at a speed of 175 µL/min.…”
Section: Resultsmentioning
confidence: 99%
“…Reaching equilibrium, or a steady state, is desirable as this gives the assay more stability even when having small differences in conditions between tests [ 75 , 76 ]. At 50 µL/min, the mixing rate will be lowest, which results in a lower magnitude of the measured agglutination signal, while simultaneously taking more time to reach a steady state.…”
Section: Resultsmentioning
confidence: 99%
“…Clinical microfluidic LOC for detecting and quantifying diagnostic markers of varied diseases are already commercialized: (a) cardiac injury markers such as myoglobin, creatinine kinase-MB (CK-MB), 22 troponin I, and B-type natriuretic peptide (BNP); (b) C-reactive protein (CRP) blood test marker of body inflammation diseases; (c) markers of carcinogenic diseases such as PSA, tumor necrosis factor-α (TNFα), liver cancer marker, α-fetoprotein (AFP), and carcinoembryonic antigen (CEA); and (d) markers of infectious diseases such as CD4 + T lymphocyte counting for monitoring the human immunodeficiency virus (HIV) and specific markers of dengue fever, influenza A, hepatitis C, malaria, and tuberculosis [ 203 ].…”
Section: Spot Tests In Practice: Past and Present Of This Classical Methodsmentioning
confidence: 99%
“…The same phenomenon can be observed on the top surface of the droplet, as right above the heating source, the temperature is higher than surrounding areas, so the flow is driven from were above the heating source towards the triple-phase contact point on the two sides. Due to the existence of capillary flow the direction of which is from the liquid phase to the solid phase [39], the flow pattern near the triple-phase contact point is always from the bottom upwards, thus resulting in the flow caused by the Marangoni effect kept away from the droplet edge. By comparing the size of the upper vortexes and the lower ones, it can be found that for droplets with smaller contact angles, the flow caused by upper surface tension gradient is more substantial.…”
Section: Simulation Of the Droplet Evaporation Under Local Heatingmentioning
confidence: 99%